☰

Joseph P. Antonios - Publications

Affiliations: 
2007-2019 Neuroscience University of California, Los Angeles, Los Angeles, CA 
 2019- Neurosurgery Yale University, New Haven, CT 
Area:
Immunology, Glioblastoma
Tree Info Grants Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications. 15: 4800. PMID 38839763 DOI: 10.1038/s41467-024-48995-7  0.513
2024 Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications. 15: 3882. PMID 38719809 DOI: 10.1038/s41467-024-48073-y  0.598
2023 Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. Research Square. PMID 37790490 DOI: 10.21203/rs.3.rs-3287211/v1  0.608
2020 Antonios JP, Everson RG, Mochizuki A, Khattab S, Soto H, Romiyo P, Sun MZ, Moughon D, Billingslea-Yoon E, Odesa S, Li G, Kawaguchi E, Salazar A, Yong W, Schlossman J, et al. Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Pr13  0.575
2020 Chavez C, Everson R, Orpilla J, Lee A, Khattab S, Antonios J, Salazar A, Cloughesy T, Liau L, Sun L, Hugo W, Prins R. CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS Neuro-Oncology. 22: ii36-ii37. DOI: 10.1093/neuonc/noaa215.152  0.451
2019 Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, et al. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology. PMID 30838489 DOI: 10.1007/S11060-019-03126-X  0.502
2019 Sun M, Orpilla J, Contreras E, Treger J, Molaie D, Tsang J, Antonios J, Wang A, Liau L, Prins R, Everson R. IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA Neuro-Oncology. 21: vi129-vi130. DOI: 10.1093/Neuonc/Noz175.542  0.526
2018 Davidson TB, Lee AH, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki AY, Antonios JP, Garcia AJ, Kotecha N, Bayless NL, et al. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30498094 DOI: 10.1158/1078-0432.Ccr-18-1176  0.561
2018 Everson RG, Antonios JP, Liau LM. Cell-Based Immunotherapy of Gliomas. Progress in Neurological Surgery. 32: 90-100. PMID 29990977 DOI: 10.1159/000469683  0.63
2018 Antonios JP, Soto H, Everson RG, Wang AC, Bethel J, Radu C, Ellingson B, Phelps M, Cloughesy TF, Prins RM, Liau LM. 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques Neurosurgery. 65: 120-120. DOI: 10.1093/Neuros/Nyy303.214  0.478
2018 Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION Neuro-Oncology. 20: vi10-vi10. DOI: 10.1093/Neuonc/Noy148.034  0.554
2017 Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America. PMID 28874539 DOI: 10.1073/Pnas.1706689114  0.605
2017 Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios JP, Kasahara N, Yang I, Prins RM, Braun J, Gordon LK, Wadehra M. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. Journal of Neuro-Oncology. PMID 28597184 DOI: 10.1007/S11060-017-2507-8  0.371
2017 Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology. PMID 28115578 DOI: 10.1093/Neuonc/Now287  0.652
2017 Soto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI Neuro-Oncology. 19: vi149-vi150. DOI: 10.1093/Neuonc/Nox168.611  0.557
2016 Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. Jci Insight. 1. PMID 27453950 DOI: 10.1172/Jci.Insight.87059  0.631
2016 Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong WH, Davidson TB, Li G, Liau LM, et al. TCR sequencing can identify and track glioma-infiltrating T cells after DC vaccination. Cancer Immunology Research. PMID 26968205 DOI: 10.1158/2326-6066.Cir-15-0240  0.655
2016 Sedighim S, Hsu M, Wang T, Everson RG, Tucker A, Antonios JP, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson TB, Li G, Liau LM, et al. Abstract 767: TCR sequencing can identify and track tumor-specific T cell populations and is a predictive biomarker of response to DC vaccination in glioblastoma patients Cancer Research. 76: 767-767. DOI: 10.1158/1538-7445.Am2016-767  0.554
2016 Antonios J, Soto H, Everson R, Orpilla J, Shin N, Moughon D, Sedighim S, Treger J, Odesa S, Tucker A, Yong W, Cloughesy T, Prins R, Liau L. TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 18: vi203-vi203. DOI: 10.1093/Neuonc/Now212.856  0.611
2016 Everson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R. IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES Neuro-Oncology. 18: vi99-vi99. DOI: 10.1093/Neuonc/Now212.412  0.639
2016 Antonios J, Soto H, Everson R, Orpilla J, Shin N, Nathanson D, Harris R, Sadeghi S, Ellingson B, Liau L, Prins R. IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMA Neuro-Oncology. 18: vi92-vi92. DOI: 10.1093/Neuonc/Now212.384  0.603
2015 Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology. PMID 26330563 DOI: 10.1093/Neuonc/Nov153  0.574
2015 Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology. PMID 26113557 DOI: 10.1093/Neuonc/Nov106  0.445
2015 Antonios JP, Everson RG, Liau LM. Dendritic cell immunotherapy for brain tumors. Journal of Neuro-Oncology. 123: 425-32. PMID 26037466 DOI: 10.1007/S11060-015-1830-1  0.638
2015 Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P393  0.676
2015 Antonios J, Soto H, Orpilla J, Shin N, Everson R, Liau L, Prins R. TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT Neuro-Oncology. 17: v214.8-v215. DOI: 10.1093/Neuonc/Nov236.04  0.658
2015 Sedighim S, Hsu M, Antonios J, Emerson R, Yusko E, Sanders C, Davidson T, Liau L, Prins R. IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS Neuro-Oncology. 17: v109.4-v110. DOI: 10.1093/Neuonc/Nov218.11  0.645
2015 Kato Y, Scharnweber R, Inagaki A, Kamijima S, Hickey M, Lisiero D, Hermann K, Soto H, Antonios J, Sedighim S, Okada H, Liau L, Klatzmann D, Prins R, Kashara N. IMPS-19RETROVIRAL REPLICATING VECTOR-MEDIATED DELIVERY OF AN IMMUNODOMINANT NEO-ANTIGEN EPITOPE TARGET FOR VIRO-IMMUNOTHERAPY IN EXPERIMENTAL GLIOMA Neuro-Oncology. 17: v117.2-v117. DOI: 10.1093/Neuonc/Nov217.19  0.53
2014 Kruse C, Liau L, Prins R, Antonios J, Ha E, Kasahara N, Soto H, Yang I. Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment Neuroimmunology and Neuroinflammation. 1: 66. DOI: 10.4103/2347-8659.139717  0.61
2014 Antonios J, Soto H, Harris R, Nathanson D, Sadeghi S, Ellingson B, Liau L, Prins R. IT-01 * PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA Neuro-Oncology. 16: v110-v110. DOI: 10.1093/Neuonc/Nou258.1  0.612
Show low-probability matches.